许立军,谢 辉,周毅彬,臧亚晨,朱 进.血清HMGB1、CTCs、AAPR与腹腔镜前列腺癌根治术患者术后生化复发的关系[J].现代生物医学进展英文版,2024,(9):1726-1730. |
血清HMGB1、CTCs、AAPR与腹腔镜前列腺癌根治术患者术后生化复发的关系 |
Relationship between Serum HMGB1, CTCs and AAPR with Postoperative Biochemical Recurrence in Patients Undergoing Laparoscopic Radical Prostatectomy |
Received:November 12, 2023 Revised:December 18, 2023 |
DOI:10.13241/j.cnki.pmb.2024.09.025 |
中文关键词: 前列腺癌 腹腔镜前列腺癌根治术 HMGB1 CTCs AAPR 生化复发 |
英文关键词: Prostate cancer Laparoscopic radical prostatectomy HMGB1 CTCs AAPR Biochemical recurrence |
基金项目:江苏省自然科学基金-面上项目(BK20191170) |
|
Hits: 132 |
Download times: 96 |
中文摘要: |
摘要 目的:探讨血清高迁移率族蛋白B1(HMGB1)、循环肿瘤细胞(CTCs)和白蛋白/碱性磷酸酶比值(AAPR)与腹腔镜前列腺癌根治术(LRP)患者术后生化复发的关系。方法:选取苏州大学附属第二医院于2018年1月至2020年7月收治的169例LRP患者,根据术后是否发生生化复发分为生化复发组和非生化复发组。检测血清HMGB1、外周血CTCs并计算AAPR。采用多因素Logistic回归分析LRP患者术后生化复发的影响因素,采用受试者工作特征(ROC)曲线分析血清HMGB1、CTCs和AAPR对LRP患者术后生化复发的预测价值。结果:随访2年,169例LRP患者术后生化复发发生率为25.44%(43/169)。与非生化复发组比较,生化复发组血清HMGB1和CTCs升高,AAPR降低(P<0.05)。多因素Logistic回归分析显示,临床分期T2期、前列腺特异性抗原(PSA)>20 ng/mL、HMGB1、CTCs升高和Gleason评分8分为LRP患者术后生化复发的独立危险因素,游离前列腺特异性抗原/总前列腺特异性抗原(fPSA/tPSA)、AAPR升高为独立保护因素(P<0.05)。ROC曲线分析显示,血清HMGB1联合CTCs和AAPR预测LRP患者术后生化复发的曲线下面积为0.881大于HMGB1、CTCs和AAPR单独预测。结论:血清HMGB1、CTCs和AAPR与LRP患者术后生化复发独立相关。血清HMGB1联合CTCs和AAPR预测LRP患者术后生化复发的价值较高,可能成为LRP患者术后生化复发的辅助预测指标。 |
英文摘要: |
ABSTRACT Objective: To investigate the relationship between serum high mobility group protein B1 (HMGB1), circulating tumor cells (CTCs) and albumin/alkaline phosphatase ratio (AAPR) and postoperative biochemical recurrence in patients undergoing laparoscopic radical prostatectomy (LRP). Methods: 169 patients with LRP admitted to the Second Affiliated Hospital of Soochow University from January 2018 to July 2020 were selected, and they were divided into biochemical recurrence group and non-biochemical recurrence group according to the occurrence of postoperative biochemical recurrence. Serum HMGB1, peripheral blood CTCs were detected, and AAPR was calculated. Multivariate Logistic regression was used to analyze the influencing factors of postoperative biochemical recurrence in patients with LRP, and the predictive value of serum HMGB1, CTCs and AAPR for postoperative biochemical recurrence in patients with LRP was analyzed by receiver operating characteristics (ROC) curve. Results: After 2 years of follow-up, the incidence rate of postoperative biochemical recurrence in 169 patients with LRP was 25.44% (43/169). Compared with non-biochemical recurrence group, serum HMGB1 and CTCs in the biochemical recurrence group were higher, and AAPR was lower (P<0.05). Multivariate Logistic regression analysis showed that Clinical stage T2 stage, prostate specific antigen (PSA) > 20 ng/mL, elevated HMGB1 and CTCs, Gleason score 8 scores were independent risk factors for postoperative biochemical recurrence in patients with LRP. The elevated free prostate specific antigen/total prostate specific antigen (fPSA/tPSA) and AAPR were independent protective factors (P<0.05). ROC curve analysis showed that the area under the curve predicted by serum HMGB1 combined with CTCs and AAPR for postoperative biochemical recurrence in LRP patients was 0.881, which was greater than that predicted by HMGB1, CTCs, and AAPR alone. Conclusion: Serum HMGB1, CTCs and AAPR are independently correlated with postoperative biochemical recurrence in patients with LRP. Serum HMGB1 combine with CTCs and AAPR has a high value in predicting postoperative biochemical recurrence in patients with LRP, and which may be an auxiliary predictor of postoperative biochemical recurrence in patients with LRP. |
View Full Text
View/Add Comment Download reader |
Close |